Author

L. van der Fits

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Organism:Arabidopsis· 1 Research Focus:benchmarking· 1 Assay:protein sequence· 1 Assay:protein structure· 1

Frequent Co-Authors

H. Schuitemaker· 3 shared R. C. Zahn· 3 shared D. H. Barouch· 2 shared F. Wegmann· 2 shared J. P. M. Langedijk· 2 shared J. Serroyen· 2 shared A. Chandrashekar· 1 shared A. Cook· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

H. Schuitemaker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models

E. Saeland, L. van der Fits, R. Bolder, M. Heemskerk-van der Meer, J. Drijver, Y. van Polanen, C. Vaneman, L. Tettero, F. Cox, J. Serroyen, M. J. Jorgensen, J. P. M. Langedijk, H. Schuitemaker, B. Callendret, R. C. Zahn

This study shows that combining Ad26.RSV.preF and RSV preF protein vaccine components enhances humoral, cellular, and protective immunity compared to using each component alone in preclinical models.

bioRxiv · Sep 23, 2022Immunology

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

X. He, A. Chandrashekar, R. C. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. Rosendahl Huber, L. van der Fits, E. N. Borducchi, , D. H. Barouch

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

bioRxiv · Jan 27, 2021Immunology

Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing

J. E. M. van der Lubbe, S. K. Rosendahl Huber, A. Vijayan, L. Dekking, E. van Huizen, J. Vreugdenhil, Y. Choi, M. R. M. Baert, K. Feddes-de Boer, A. Izquierdo Gil, M. van Heerden, T. J. Dalebout, S. K. Myeni, M. Kikkert, E. J. Snijder, , F. Wegmann

This study shows that a single dose of Ad26.COV2.S vaccine protects Syrian hamsters from G614 SARS-CoV-2 infection and prevents VAERD even with suboptimal immunity.

bioRxiv · Jan 8, 2021 · PreprintImmunology